Salix Announces 2021 Gastrointestinal Health Scholars Program Winners

 
 

- Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced the winners of its 2021 Salix Gastrointestinal Health Scholars Program. Ten students living with a GI disease will each receive a $10,000 scholarship; a total of $100,000 in scholarships was awarded.

 

"We created the Salix Gastrointestinal Health Scholars Program to assist students with GI conditions as they pursue their higher education goals, because we recognize that living with a GI condition can make it challenging and stressful to pursue higher education," said Robert Spurr , president, Salix Pharmaceuticals. "We were moved by the stories this year's recipients shared with us about how they have uniquely had to manage their GI conditions but refused to let them get in the way of their education, and we are honored to help support them."

 

The 2021 awardees were selected from more than 150 applications. As part of the process, applicants were required to submit essays describing how their GI condition has impacted their educational journey, as well as the role their health care provider played in helping them reach their goals. The applications were reviewed by an independent panel of judges.

 

The Salix Gastrointestinal Health Scholars Program recognizes students across a wide range of educational pursuits, with scholarships in four categories, including the Undergraduate Scholar Awards for those pursuing undergraduate degrees; the Graduate Scholar Awards for those pursuing graduate degrees; the Working Parent's Scholar Award for parents pursuing undergraduate, vocational/technical or graduate degrees; and the Single Parent's Scholar Award for single parents pursuing undergraduate, vocational/technical or graduate degrees.

 

The 2021 Salix Gastrointestinal Health Scholars Program recipients are:

 
  •   Undergraduate Scholar Awards  
  •  
    •   Madeleine Huwe , Sherwood, Ore. George Fox University  
    •  
    •   Lillian Munro , Ocean Springs, Miss. – The University of Mississippi  
    •  
    •   Yetunde Olateru-Olagbegi , Medford, N.Y. New York University  
    •  
    •   Amelia Williams , Lafayette, Ind. – Purdue Universit
    •  
  •   Graduate Scholar Awards  
  •  
    •   Madison Folsom , Lancaster, N.Y. Canisius College  
    •  
    •   Margaux Herrera , El Portal, Fla. Florida State University  
    •  
    •   Olivia Perez , Coral Gables, Fla. Nova Southeastern University  
    •  
    •   Blake Sisson , Angier, N.C. , – Campbell University  
    •  
  •   Working Parent's Scholar Award  
  •  
    •   Audriana Duvall , Baltimore, Md. University of Baltimore  
    •  
  •   Single Parent's Scholar Award  
  •  
    •   Amy Devlin , Worcester, Mass. Maharishi International University  
    •  

"I'm so grateful to receive this scholarship as I pursue my higher education in nursing school," said Madeleine Huwe , a recipient of the Undergraduate Scholar's Award. "It's wonderful to feel seen and imagine my future in health care utilizing my experience as a patient to help improve the system."

 

To learn more about the Salix Gastrointestinal Health Scholars Program visit www.salix.com/scholarship . The 2022 Salix Gastrointestinal Health Scholars Award will begin accepting applications in early 2022.

 

  About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey . For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn .

 

  About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

 

  ©2021 Salix Pharmaceuticals or its affiliates.
  SAL.0102.USA.21  

 
 
          
 

   Investor Contact:   

 
 

   Media Contact:   

 
 

  Arthur Shannon  

 
 

  Lainie Keller  

 
 

   arthur.shannon@bauschhealth.com   

 
 

   lainie.keller@bauschhealth.com   

 
 

  (514) 856-3855  

 
 

  (908) 927-1198  

 
 

  (877) 281-6642 (toll free)  

 
 
 
 

 

 
 

  Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.) 

 
 

 

 
 

   

 
 

 

 

 

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/salix-announces-2021-gastrointestinal-health-scholars-program-winners-301337617.html  

 

SOURCE Bausch Health Companies Inc.

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Bausch Health Companies Inc.

Bausch Health Companies Inc.

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.

illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×